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A 60‐year‐old woman with white blood cell count of 70 × 10^3^/μL with monocytosis, hemoglobin 11.2 g/dL, platelets 89 × 10^3^/µL, and creatinine 1.41 mg/dL had bone marrow biopsy demonstrating chronic myelomonocytic leukemia (CMML). Subsequent nephrectomy revealed renal cell carcinoma (RCC). Proximal tubules uninvolved by RCC contained abundant eosinophilic droplets confirmed as lysozyme (Figure [1](#ccr32188-fig-0001){ref-type="fig"}A,B). Serum and urine lysozyme concentrations were \>10 µg/mL. She received 5‐azacitidine with reduction in monocytosis and serum lysozyme and creatinine, with complete normalization of these parameters following allogeneic stem cell transplant.

![Lysozyme nephropathy in CMML. A, H&E stain demonstrating bright eosinophilic cytoplasmic granules within renal proximal tubule cells. B, Lysozyme immunohistochemical stain highlighting cytoplasmic droplets within the proximal tubule. C, Correlation of absolute monocyte count of newly diagnosed CMML patients with plasma lysozyme levels. D, Correlation of plasma lysozyme levels with concurrent serum creatinine measurements](CCR3-7-1263-g001){#ccr32188-fig-0001}

Lysozyme is a bacteriolytic enzyme detectable in monocytes. Lysozyme is reabsorbed by renal proximal tubule cells until concentrations exceed 45 μg/mL and urinary excretion is observed.[1](#ccr32188-bib-0001){ref-type="ref"} Increased serum and urine lysozyme are seen in diseases characterized by monocytic proliferation, including myeloid leukemia.[1](#ccr32188-bib-0001){ref-type="ref"}

We measured plasma lysozyme in CMML patients at diagnosis (N = 18), on therapy with hypomethylating agents (N = 10), and in healthy controls (N = 6). Median concentrations were highest at diagnosis (7.5 µg/mL) and correlated with monocyte count and serum creatinine (Figure [1](#ccr32188-fig-0001){ref-type="fig"}C,D). Treatment reduced concentrations (1.59 µg/mL), without reaching those of controls (0.68 µg/mL).

Renal impairment in CMML may reflect age‐related comorbidities. However, intravenous lysozyme causes tubular damage in rats, arguing that monocyte‐derived lysozyme could cause renal injury in CMML that is amenable to reversal with cytoreduction.[2](#ccr32188-bib-0002){ref-type="ref"}
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